Navigating the Brain: Harnessing Endogenous Cellular Hitchhiking for Targeting Neoplastic and Neuroinflammatory Diseases

Asian Journal of Pharmaceutical Sciences, Год журнала: 2025, Номер unknown, С. 101040 - 101040

Опубликована: Фев. 1, 2025

Язык: Английский

---

Novel neutrophil targeting platforms in treating Glioblastoma: Latest evidence and therapeutic approaches

International Immunopharmacology, Год журнала: 2025, Номер 150, С. 114173 - 114173

Опубликована: Фев. 11, 2025

Язык: Английский

---

Neutrophils: Linking Inflammation to Thrombosis and Unlocking New Treatment Horizons

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 1965 - 1965

Опубликована: Фев. 25, 2025

Neutrophils play a key role in inflammatory responses and thrombosis, but their complex interactions disease pathogenesis are not fully understood. This review examines the multifaceted roles of neutrophils, focusing on activation, cytokine release, formation neutrophil extracellular traps (NETs), which contribute to host defense thrombosis. We discuss interaction between inflammation coagulation, direct effect neutrophils thrombus stability, involvement pathological thrombotic diseases. The therapeutic potential drug loading treatment as well clinical implications future research directions, highlighted. aim this is gain insight into critical neutrophil-inflammation-thrombus axis its target for diseases suggest possible directions neutrophil-loaded therapy

Язык: Английский

---

New Insights on the Potential Role of Pyroptosis in Parkinson’s Neuropathology and Therapeutic Targeting of NLRP3 Inflammasome with Recent Advances in Nanoparticle-Based miRNA Therapeutics

Molecular Neurobiology, Год журнала: 2025, Номер unknown

Опубликована: Март 18, 2025

Язык: Английский

---

Unlocking the Gates: Therapeutic Agents for Noninvasive Drug Delivery Across the Blood-Brain Barrier

Molecular Pharmaceutics, Год журнала: 2024, Номер unknown

Опубликована: Сен. 26, 2024

The blood-brain barrier (BBB) is a highly selective network of various cell types that acts as filter between the blood and brain parenchyma. Because this, BBB remains major obstacle for drug delivery to central nervous system (CNS). In recent years, there has been focus on developing modifiable platforms, such monoclonal antibodies (mAbs), nanobodies (Nbs), peptides, nanoparticles, both therapeutic agents carriers targeted treat cancers diseases. Methods bypassing can be invasive or noninvasive. Invasive techniques, transient disruption using low pulse electrical fields intracerebroventricular infusion, lack specificity have numerous safety concerns. this review, we will noninvasive transport mechanisms offer high levels biocompatibility, personalization, are regarded generally safer than their counterparts. Modifiable platforms designed noninvasively traverse through one more following pathways: passive diffusion physio-pathologically disrupted BBB, adsorptive-mediated transcytosis, receptor-mediated shuttle-mediated somatic gene transfer. Through understanding pathways, new applications, including Chimeric Antigen Receptors T-cell (CAR-T) therapy, approaches across emerging.

Язык: Английский

---

Nanotechnology used for siRNA delivery for the treatment of neurodegenerative diseases: Focusing on Alzheimer’s disease and Parkinson’s disease

International Journal of Pharmaceutics, Год журнала: 2024, Номер 666, С. 124786 - 124786

Опубликована: Окт. 6, 2024

Язык: Английский

---